Updated Monograph Opens the Market for ResistAid in Australia

Current clinical evidence demonstrates the ability of ResistAid to selectively call upon both the non-specific, cellular response, as well as the adaptive immune response in healthy adults.

6 Jun 2012 --- Lonza has announced that larch arabinogalactan is now allowed for use in dietary supplements according to an updated monograph from the Australian Government’s Department of Health and Ageing, and Therapeutic Goods Administration (TGA). Lonza offers larch arabinogalactan, which is positioned for immune health under the brand name ResistAid.

Lonza continues to evaluate and open new markets based on the ever-building ResistAid immune research. Current clinical evidence demonstrates the ability of ResistAid to selectively call upon both the non-specific, cellular response, as well as the adaptive immune response in healthy adults. Through clinical research ResistAid has also been shown to provide an immunomodulatory effect, enhancing the appropriate response to an antigen, as opposed to indiscriminately enhancing other arms of the immune system that would not be expected to respond. Therefore, it has the ability to enhance the body’s natural immune function during an immune challenge.

Details on the updated monograph can be found under
http://www.tga.gov.au/industry/cm-cg-larix-arabinogalactan.htm